Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia

E. M. Mortensen, M. J. Pugh, L. A. Copeland, M. I. Restrepo, J. E. Cornell, A. Anzueto, J. A. Pugh

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Recent studies suggest that statins and angiotensin-converting enzyme (ACE) inhibitors may have beneficial effects for some types of infections. The present study aimed to examine the association of outpatient use of these medications on 30-day mortality for subjects aged >65 yrs and hospitalised with community-acquired pneumonia. A retrospective national cohort study was conducted using the Department of Veterans Affairs administrative data including subjects aged ≥65 yrs hospitalised with community-acquired pneumonia, and having ≥1 yr of prior Veterans Affairs outpatient care. In total, 8,652 subjects were identified with a mean age of 75 yrs, 98.6% were male, and 9.9% of subjects died within 30 days of presentation. In this cohort, 18.1% of subjects were using statins and 33.9% were using ACE inhibitors. After adjusting for potential confounders, current statin use (odds ratio (OR) 0.54, 95% confidence interval (CI) 0.42-0.70) and ACE inhibitor use (OR 0.80, 95% CI 0.68-0.89) were significantly associated with decreased 30-day mortality. Use of statins and angiotensin-converting enzyme inhibitors prior to admission is associated with decreased mortality in subjects hospitalised with community-acquired pneumonia. Randomised controlled trials are needed to examine whether the use of these medications in patients hospitalised with community-acquired pneumonia may be beneficial. Copyright

Original languageEnglish (US)
Pages (from-to)611-617
Number of pages7
JournalEuropean Respiratory Journal
Volume31
Issue number3
DOIs
StatePublished - Mar 2008

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Angiotensin-Converting Enzyme Inhibitors
Pneumonia
Mortality
Veterans
Odds Ratio
Confidence Intervals
Ambulatory Care
Cohort Studies
Outpatients
Randomized Controlled Trials
Infection

Keywords

  • 3-Hydroxl-3-methyl-glutaryl-CoA reductase inhibitor
  • Angiotensin-converting enzyme inhibitor
  • Mortality
  • Pneumonia

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. / Mortensen, E. M.; Pugh, M. J.; Copeland, L. A.; Restrepo, M. I.; Cornell, J. E.; Anzueto, A.; Pugh, J. A.

In: European Respiratory Journal, Vol. 31, No. 3, 03.2008, p. 611-617.

Research output: Contribution to journalArticle

Mortensen, E. M. ; Pugh, M. J. ; Copeland, L. A. ; Restrepo, M. I. ; Cornell, J. E. ; Anzueto, A. ; Pugh, J. A. / Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. In: European Respiratory Journal. 2008 ; Vol. 31, No. 3. pp. 611-617.
@article{e55f031951e84cafa9135d5ed6d749f8,
title = "Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia",
abstract = "Recent studies suggest that statins and angiotensin-converting enzyme (ACE) inhibitors may have beneficial effects for some types of infections. The present study aimed to examine the association of outpatient use of these medications on 30-day mortality for subjects aged >65 yrs and hospitalised with community-acquired pneumonia. A retrospective national cohort study was conducted using the Department of Veterans Affairs administrative data including subjects aged ≥65 yrs hospitalised with community-acquired pneumonia, and having ≥1 yr of prior Veterans Affairs outpatient care. In total, 8,652 subjects were identified with a mean age of 75 yrs, 98.6{\%} were male, and 9.9{\%} of subjects died within 30 days of presentation. In this cohort, 18.1{\%} of subjects were using statins and 33.9{\%} were using ACE inhibitors. After adjusting for potential confounders, current statin use (odds ratio (OR) 0.54, 95{\%} confidence interval (CI) 0.42-0.70) and ACE inhibitor use (OR 0.80, 95{\%} CI 0.68-0.89) were significantly associated with decreased 30-day mortality. Use of statins and angiotensin-converting enzyme inhibitors prior to admission is associated with decreased mortality in subjects hospitalised with community-acquired pneumonia. Randomised controlled trials are needed to examine whether the use of these medications in patients hospitalised with community-acquired pneumonia may be beneficial. Copyright",
keywords = "3-Hydroxl-3-methyl-glutaryl-CoA reductase inhibitor, Angiotensin-converting enzyme inhibitor, Mortality, Pneumonia",
author = "Mortensen, {E. M.} and Pugh, {M. J.} and Copeland, {L. A.} and Restrepo, {M. I.} and Cornell, {J. E.} and A. Anzueto and Pugh, {J. A.}",
year = "2008",
month = "3",
doi = "10.1183/09031936.00162006",
language = "English (US)",
volume = "31",
pages = "611--617",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "3",

}

TY - JOUR

T1 - Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia

AU - Mortensen, E. M.

AU - Pugh, M. J.

AU - Copeland, L. A.

AU - Restrepo, M. I.

AU - Cornell, J. E.

AU - Anzueto, A.

AU - Pugh, J. A.

PY - 2008/3

Y1 - 2008/3

N2 - Recent studies suggest that statins and angiotensin-converting enzyme (ACE) inhibitors may have beneficial effects for some types of infections. The present study aimed to examine the association of outpatient use of these medications on 30-day mortality for subjects aged >65 yrs and hospitalised with community-acquired pneumonia. A retrospective national cohort study was conducted using the Department of Veterans Affairs administrative data including subjects aged ≥65 yrs hospitalised with community-acquired pneumonia, and having ≥1 yr of prior Veterans Affairs outpatient care. In total, 8,652 subjects were identified with a mean age of 75 yrs, 98.6% were male, and 9.9% of subjects died within 30 days of presentation. In this cohort, 18.1% of subjects were using statins and 33.9% were using ACE inhibitors. After adjusting for potential confounders, current statin use (odds ratio (OR) 0.54, 95% confidence interval (CI) 0.42-0.70) and ACE inhibitor use (OR 0.80, 95% CI 0.68-0.89) were significantly associated with decreased 30-day mortality. Use of statins and angiotensin-converting enzyme inhibitors prior to admission is associated with decreased mortality in subjects hospitalised with community-acquired pneumonia. Randomised controlled trials are needed to examine whether the use of these medications in patients hospitalised with community-acquired pneumonia may be beneficial. Copyright

AB - Recent studies suggest that statins and angiotensin-converting enzyme (ACE) inhibitors may have beneficial effects for some types of infections. The present study aimed to examine the association of outpatient use of these medications on 30-day mortality for subjects aged >65 yrs and hospitalised with community-acquired pneumonia. A retrospective national cohort study was conducted using the Department of Veterans Affairs administrative data including subjects aged ≥65 yrs hospitalised with community-acquired pneumonia, and having ≥1 yr of prior Veterans Affairs outpatient care. In total, 8,652 subjects were identified with a mean age of 75 yrs, 98.6% were male, and 9.9% of subjects died within 30 days of presentation. In this cohort, 18.1% of subjects were using statins and 33.9% were using ACE inhibitors. After adjusting for potential confounders, current statin use (odds ratio (OR) 0.54, 95% confidence interval (CI) 0.42-0.70) and ACE inhibitor use (OR 0.80, 95% CI 0.68-0.89) were significantly associated with decreased 30-day mortality. Use of statins and angiotensin-converting enzyme inhibitors prior to admission is associated with decreased mortality in subjects hospitalised with community-acquired pneumonia. Randomised controlled trials are needed to examine whether the use of these medications in patients hospitalised with community-acquired pneumonia may be beneficial. Copyright

KW - 3-Hydroxl-3-methyl-glutaryl-CoA reductase inhibitor

KW - Angiotensin-converting enzyme inhibitor

KW - Mortality

KW - Pneumonia

UR - http://www.scopus.com/inward/record.url?scp=42949123466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42949123466&partnerID=8YFLogxK

U2 - 10.1183/09031936.00162006

DO - 10.1183/09031936.00162006

M3 - Article

C2 - 17959631

AN - SCOPUS:42949123466

VL - 31

SP - 611

EP - 617

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 3

ER -